Viking Therapeutics Inc. (NASDAQ: VKTX) announced results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an oral tablet formulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE